FDA reviews Sanofi and Regeneron’s Dupixent label expansion for urticaria
The FDA has accepted Sanofi and Regeneron’s application to expand Dupixent’s use, with a decision expected by April 2025.
Managed Healthcare Executive3d
FDA Sets Date For Resubmitted Dupixent in Inflammatory Skin Disease
The FDA has provided a date of April 18, 2025, to review the application for Dupixent to treat patients with chronic ...
Dupixent® (dupilumab) sBLA Accepted for FDA Review for the Treatment of Chronic Spontaneous Urticaria (CSU)
Resubmission includes new pivotal data which confirm Dupixent significantly reduced itch and hive activityMore than 300,000 people in the U.S.
Yahoo Finance5d
Regeneron/Sanofi's Dupixent Approval Signals Major Treatment Breakthrough For Smokers' Lung Disease
After years of limited advancements in chronic obstructive pulmonary disease (COPD) treatment, patients now have new options.
Promising Advancements and Strategic Positioning Propel Apogee Therapeutics, Inc. to a Buy Rating
TD Cowen analyst Tyler Van Buren has maintained their bullish stance on APGE stock, giving a Buy rating on October 28. Tyler Van Buren has ...
Apogee Therapeutics Provides Pipeline Progress and Reports Third Quarter 2024 Financial Results
Continued execution across all programs, including positive results up to nine months from APG777 Phase 1 trial that continue to support potential best-in-class profile On track to report Phase 2 Part ...